A. Wang

746 total citations · 1 hit paper
10 papers, 401 citations indexed

About

A. Wang is a scholar working on Oncology, Surgery and Pathology and Forensic Medicine. According to data from OpenAlex, A. Wang has authored 10 papers receiving a total of 401 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Oncology, 2 papers in Surgery and 2 papers in Pathology and Forensic Medicine. Recurrent topics in A. Wang's work include Cancer Immunotherapy and Biomarkers (3 papers), Colorectal Cancer Treatments and Studies (2 papers) and Gastric Cancer Management and Outcomes (2 papers). A. Wang is often cited by papers focused on Cancer Immunotherapy and Biomarkers (3 papers), Colorectal Cancer Treatments and Studies (2 papers) and Gastric Cancer Management and Outcomes (2 papers). A. Wang collaborates with scholars based in United States, Germany and Belgium. A. Wang's co-authors include S.B. Kim, Konstantinos Tryfonidis, Lei Yin, Y.H. Park, Vassiliki Karantza, Sherene Loi, Roberto Salgado, Theodoros Foukakis, Peter Schmid and Seock‐Ah Im and has published in prestigious journals such as Applied Physics Letters, Scientific Reports and Annals of Oncology.

In The Last Decade

A. Wang

8 papers receiving 398 citations

Hit Papers

Pembrolizumab plus chemotherapy as neoadjuvant treatment ... 2020 2026 2022 2024 2020 50 100 150 200 250
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort KEYNOTE-173 study
    2020 279 citations Peter Schmid, Roberto Salgado et al. Annals of Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
A. Wang United States 5 261 97 87 83 80 10 401
Yuping Sun China 12 167 0.6× 86 0.9× 46 0.5× 75 0.9× 49 0.6× 61 351
Yufei Xing China 12 132 0.5× 66 0.7× 80 0.9× 58 0.7× 39 0.5× 34 404
Yiping Zhang China 9 367 1.4× 35 0.4× 35 0.4× 294 3.5× 70 0.9× 24 584
Yuxiang Deng China 12 174 0.7× 18 0.2× 65 0.7× 74 0.9× 59 0.7× 34 360
Shota Ida Japan 12 193 0.7× 101 1.0× 118 1.4× 82 1.0× 20 0.3× 30 393
Sergej Osinsky Ukraine 11 133 0.5× 48 0.5× 86 1.0× 65 0.8× 44 0.6× 29 390
Lucile Dondaine France 9 238 0.9× 109 1.1× 26 0.3× 69 0.8× 35 0.4× 12 408
Changli Peng China 6 107 0.4× 104 1.1× 41 0.5× 42 0.5× 69 0.9× 8 324
Kim de Lange Netherlands 10 218 0.8× 136 1.4× 44 0.5× 113 1.4× 31 0.4× 18 435

Countries citing papers authored by A. Wang

Since Specialization
Citations

This map shows the geographic impact of A. Wang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by A. Wang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites A. Wang more than expected).

Fields of papers citing papers by A. Wang

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by A. Wang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by A. Wang. The network helps show where A. Wang may publish in the future.

Co-authorship network of co-authors of A. Wang

This figure shows the co-authorship network connecting the top 25 collaborators of A. Wang. A scholar is included among the top collaborators of A. Wang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with A. Wang. A. Wang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

10 of 10 papers shown
1.
Zhang, Rong, Bingtao Zhai, A. Wang, et al.. (2025). Research Progress of Docetaxel Nano-Drug Delivery System in the Treatment of Breast Cancer. International Journal of Nanomedicine. Volume 20. 14571–14611.
2.
Wang, A., et al.. (2025). Electron mobility in AlN from first principles. Applied Physics Letters. 127(7).
3.
4.
Wang, A., Kyle Bushick, Nick Pant, et al.. (2024). Electron mobility of SnO2 from first principles. Applied Physics Letters. 124(17). 7 indexed citations
5.
Ben‐Aharon, Irit, Ayala Hubert, Deirdre Jill Cohen, et al.. (2022). 1223P First-line lenvatinib (Len) + pembrolizumab (Pembro) + chemotherapy (Chemo) vs chemo in advanced/metastatic gastroesophageal adenocarcinoma: LEAP-015 safety run-in. Annals of Oncology. 33. S1108–S1108. 4 indexed citations
6.
Passhak, Maria, Taehyun Kim, Ravit Geva, et al.. (2022). P-81 Phase 3 study of MK4280A (coformulated favezelimab and pembrolizumab) versus standard of care in previously treated PD-L1–positive metastatic colorectal cancer (mCRC). Annals of Oncology. 33. S277–S277. 3 indexed citations
7.
8.
Laethem, J-L. van, Ivan Borbath, Mark Karwal, et al.. (2021). 933P Updated results for pembrolizumab (pembro) monotherapy as first-line therapy for advanced hepatocellular carcinoma (HCC) in the phase II KEYNOTE-224 study. Annals of Oncology. 32. S819–S819. 1 indexed citations
9.
Wang, A., Ryan Kingsbury, Matthew J. McDermott, et al.. (2021). A framework for quantifying uncertainty in DFT energy corrections. Scientific Reports. 11(1). 15496–15496. 99 indexed citations
10.
Schmid, Peter, Roberto Salgado, Y.H. Park, et al.. (2020). Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort KEYNOTE-173 study. Annals of Oncology. 31(5). 569–581. 279 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Yuping Sun Breakdown of academic impact, for papers by Yufei Xing Breakdown of academic impact, for papers by Yiping Zhang Breakdown of academic impact, for papers by Yuxiang Deng Breakdown of academic impact, for papers by Shota Ida Breakdown of academic impact, for papers by Sergej Osinsky Breakdown of academic impact, for papers by Lucile Dondaine Breakdown of academic impact, for papers by Changli Peng Breakdown of academic impact, for papers by Kim de Lange
Rankless by CCL
2026